English  |  正體中文  |  简体中文  |  Items with full text/Total items : 16909/19260 (88%)
Visitors : 7555540      Online Users : 441
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: http://ir.cnu.edu.tw/handle/310902800/27727


    標題: Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin
    作者: Huang, Chung-Feng
    Huang, Jee-Fu
    Yang, Jeng-Fu
    Hsieh, Ming-Yen
    Lin, Zu-Yau
    Chen, Shinn-Cherng
    Wang, Liang-Yen
    Juo, Suh-Hang Hank
    Chen, Ku-Chung
    Chuang, Wan-Long
    Kuo, Hsing-Tao
    Dai, Chia-Yen
    Yu, Ming-Lung
    貢獻者: 老人服務事業管理系
    關鍵字: Hcv
    Il-28B
    Tailored Regimen
    Treatment
    日期: 2012
    上傳時間: 2014-03-24 15:22:57 (UTC+8)
    出版者: Elsevier Science Bv
    摘要: Background & Aims: A substantial proportion of hepatitis C virus genotype 1 (HCV-1) patients achieved a sustained virological response (SVR, HCV RNA seronegative throughout 24 weeks of post-treatment follow-up) after 24 weeks peginterferon/ribavirin therapy. We explored the role of interleukin-28B genotype in identifying patients who responded to the regimen.Methods: Interleukin-28B rs8099917 genotype was determined in 226 HCV-1 patients with 24 weeks peginterferon/ribavirin.Results: Compared to patients with rs8099917 TG/GG genotype, those with TT genotype had significantly higher rapid virological response (RVR, HCV RNA seronegative at treatment week 4, 54.0% vs. 17.9%, p <0.001) and SVR (64.7% vs. 25.6%, p <0.001) rates, and lower relapse rate (28.0% vs. 54.5%, p = 0.01). Logistic regression analysis revealed that the strongest factor predictive of a RVR was the carriage of rs8099917 TT genotype (odds ratio/95% confidence intervals [OR/CI]: 6.24/2.34-16.63), followed by lower viral loads (OR/CI: 5.29/2.81-9.93) and age (OR/CI: 0.94/0.919.97). The most important factor predictive of an SVR was the attainment of a RVR (OR/CI: 22.23/9.22-53.58), followed by the carriage of rs8099917 TT genotype (OR/CI: 3.38/1.18-9.65), lower viral loads (OR/CI: 2.23/1.00-4.93) and ribavirin exposure dose (OR/CI: 1.17/1.06-1.30). The determinant power of rs8099917 genotype on SVR was mainly restricted to non-RVR patients, particularly those with higher baseline viral loads. Combination of the two pretreatment predictors, interleukin-28B genotype and baseline viral loads, could predict treatment efficacy with a positive predictive value of 80% and a negative predictive value of 91%.Conclusions: Interleukin-28B genotype could help identifying patients who are or are not candidates for an abbreviated regimen before treatment. (C) 2011 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
    Appears in Collections:[老人服務事業管理系] 期刊論文

    Files in This Item:

    File Description SizeFormat
    index.html0KbHTML518View/Open


    All items in CNU IR are protected by copyright, with all rights reserved.


    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback